ATHE: חוב כולל להון Alterity Therapeutics Ltd

The price indicator on the Alterity Therapeutics (ATHE) chart demonstrates a debt-to-equity ratio of 0.00. Alterity Therapeutics (ATHE) minimizes internal costs by outsourcing production and testing to third-party contractors. The business currently relies on raised capital to develop drugs for rare brain pathologies. The success of current tests will provide the company with exceptional demand due to the lack of available therapy methods in this niche.

The total debt-to-equity ratio measures the proportion of borrowed funds within the financing structure, determining the business's level of dependence on external creditors relative to its own equity. By analyzing the debt-to-equity leverage chart, an investor assesses the financial resilience of Alterity Therapeutics (ATHE), which is critical for ensuring the long-term trials of the ATH434 drug for the treatment of rare neurological pathologies.